Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | POLB | P06746 | 3/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | CNR1 | P21554 | 6/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | CNR2 | P34972 | 2/20 | 0.37 |
| ▸ | CASP6 | P55212 | 1/20 | 0.36 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.36 |
| ▸ | PSMD14 | O00487 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13664381 | 0.90 | L3MBTL1 (0.49) | L3MBTL1LMNAPOLBHTTCNR1 | |
| SCHEMBL13664278 | 0.82 | CNR1 (0.39) | L3MBTL1POLBCNR1TDP1GAA | |
| SCHEMBL13664482 | 0.81 | CNR1 (0.38) | L3MBTL1POLBCNR1TDP1GAA | |
| SCHEMBL13664417 | 0.80 | ALDH1A1 (0.39) | L3MBTL1POLBCNR1TDP1SMN1; SMN2 | |
| SCHEMBL13664385 | 0.80 | L3MBTL1 (0.38) | L3MBTL1POLBCNR1TDP1NPC1 | |
| SCHEMBL13664413 | 0.79 | NPC1 (0.45) | L3MBTL1POLBCNR1TDP1NPC1 | |
| SCHEMBL13664531 | 0.79 | POLB (0.41) | L3MBTL1LMNAPOLBCNR1TDP1 | |
| SCHEMBL13664148 | 0.79 | POLB (0.41) | L3MBTL1POLBCNR1TDP1NPC1 | |
| SCHEMBL13664373 | 0.78 | POLB (0.46) | L3MBTL1LMNAPOLBCNR1TDP1 | |
| SCHEMBL13664143 | 0.78 | POLB (0.46) | L3MBTL1LMNAPOLBCNR1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090253673-A1 | Substituted Pyrazoles as Ghrelin Receptor Antagonists | MERCK SHARP & DOHME CORP. | 2009-10-08 | — | — | US | disclosed |
| US-20090253673-A1 | Substituted Pyrazoles as Ghrelin Receptor Antagonists | MERCK SHARP & DOHME CORP. | 2009-10-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090253673-A1 | Substituted Pyrazoles as Ghrelin Receptor Antagonists | GIPR, GPR119, GLP1R | L3MBTL1 3707/4885LMNA 4188/4885POLB 4851/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.